For the first CAR-T therapy, early sales are weak but hopes are still sky high – STAT
YOmphFV5DLeOsnuU7zp_dO12AiON3BQ” alt=”” border=”1″ width=”80″ height=”80″/> STAT |
For the first CAR–T therapy, early sales are weak but hopes are still sky high
STAT More From Other Publishers. ASH16 Preview: New CAR T-cell Data Come at a Pivotal Moment. Miguel-Angel Perales et al., Medscape. CAR T Cells: A Look Under the Hood and Down the Road. Mark J. Adler, MD, Medscape. Amgen Discounts Cholesterol Drug, but … |
